Home › ORCHPHARMA › Filing
🔔 Get instant alerts when ORCHPHARMA files quarterly results on BSE Start free trial →
Orchid Pharma Limited (ORCHPHARMA)

Analysts/Institutional Investor Meet/Con. Call Updates

Filed: 20 Nov 2026, 12:40 IST Exchange: NSE Category: Financial Results — Earnings Call Transcript
AI summary - Q2 FY27 revenue grew 14% y-y to INR341 Cr; H1 revenue up 15% to INR645 Cr - Gross margin improved ~8 ppts to 39% in Q2; H1 margin at 36% - Q2 EBITDA rose 148% to INR52 Cr; EBITDA margin 15% vs 7% last year - Q2 PAT INR28.6 Cr vs loss of INR0.9 Cr last year; H1 PAT INR32 Cr - Working capital improved; operating cash flow INR118 Cr in H1 FY27 - Merger benefits expected to show cost savings by end FY27 - Cefiderocol project commissioning targeted Dec 2026; India launch Q3 FY27 - 7-ACA plant commissioning planned Mar 2027; capacity 1,000 MT/year - EXBLIFEP royalties run rate $3-4 million annually; commercialization progressing - No short-term margin guidance; focus on cost control and product mix - Multiple analyst queries on U.S. licensing and fundraising; no timelines given
Source: Original filing PDF — view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts BOT
🚨 ORCHPHARMA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
✓✓ 6:47 PM
🎧
Instant audio summaries2-min AI concall recap delivered with every earnings alert
📊
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
🔍
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
⚡
Instant Telegram alertsResults, board meetings, insider trades — within minutes

Add ORCHPHARMA to your watchlist — all of this, automated.

Sign in with Google
14-day Pro trial · No credit card · Cancel anytime

More on Orchid Pharma Limited

Important. The summary above is generated automatically from Orchid Pharma Limited's own public regulatory filing under SEBI LODR. Indian Stock Alerts is not a SEBI-registered Research Analyst or Investment Adviser. This page is informational, not investment advice, a recommendation to buy or sell any security, or any opinion about the company's business, governance or financial health. Always read the original filing before acting and consult a registered adviser for investment decisions.